Earlier Onset of Treatment or Increment in LT4 Dose in Screened Congenital Hypothyroidism: Which Was the More Important Factor for IQ at 7 Years?Boileau P. · Bain P. · Rives S. · Toublanc J.-E.
General Outpatient Clinic, Hôpital St-Vincent-de-Paul, Paris, France
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objective: To determine between timing and LT4 dose which was the more important factor for IQ at 7 years in screened congenital hypothyroidism (CH). Methods: 131 children with CH born from 1979 to 1994 and 30 controls were studied. Mean age at recall: 22.8 ± 1.1 days. Mean initial LT4: 5.6 ± 0.1 µg/kg/day. Results: Optimal global IQ (GIQ; 119.0 ± 1.8) was obtained for a recall ≤15 days. Results for a recall after 3 weeks were lower (107.7 ± 2.4). The IQ of infants treated before 21 days (117.1 ± 1.2) was identical to the IQ of controls (117.0 ± 2.3) whereas the IQ of those treated after this threshold was lower (108.6 ± 1.7). No significant differences for GIQ were observed with various initial LT4 doses. Infants treated with a dose of LT4 ≧6 µg/kg/day had a higher performance IQ (117.3 ± 1.8 vs. 112.8 ± 1.2) compared with those treated with a dose <6 µg/kg/day. The severity of CH and socio-economic levels were similar in all groups. Conclusion: In this study, timing appears to be the more important factor for the intellectual outcome.
© 2004 S. Karger AG, Basel
- Glorieux J, Dussault JH, Morissette J, Desjardins M, Letarte J, Guyda H: Follow-up at ages 5 and 7 years on mental development in children with hypothyroidism detected by Quebec screening program. J Pediatr 1985;107:913–919.
- Rovet J, Ehrlich R, Sorbara D: Intellectual outcome in children with fetal hypothyroidism. J Pediatr 1987;110:700–704.
- Glorieux J, Desjardins M, Letarte J, Morisette J, Dussault JH: Useful parameters to predict the eventual mental outcome of hypothyroid children. Pediatr Res 1988;24:6–8.
- Derksen-Lubsen G, Verkerk PH: Neuropsychologic development in early treated congenital hypothyroidism: Analysis of literature data. Pediatr Res 1996;39:561–566.
Touati G, Leger J, Czernichow P: Hypothyroïdie, stratégie à la phase précoce du traitement. Arch Fr Pédiatr 1991;48:461–465.
- Touati G, Leger J, Toublanc J-E, Farriaux JP, Stuckens C, Ponte C, David M, Rocchicioli P, Porquet D, Czernichow P: A thyroxine dosage of 8 μg/kg per day is appropriate for the initial treatment of the majority of infants with congenital hypothyroidism. Eur J Pediatr 1997;156:94–98.
- Bain P, Toublanc J-E: Adult height in congenital hypothyroidism: Prognostic factors and the importance of compliance with treatment. Horm Res 2002;58:136–142.
Graffar M: Une méthode de classification sociale d’échantillons de population. Courrier 1956;6:455–459.
Wechsler D: Recherches sur le WISC-III: études comparatives; in Wechsler D (ed): Wisc III, Echelle d’intelligence de Wechsler pour enfants, ed 3. Paris, ECPA, 1991, pp 208–216.
Toublanc J-E, Boileau P, Riblier E, Daubin C, Rives S: L’avenir à long terme de l’hypothyroïdie congénitale. Influence des facteurs de pronostic. Rev Fr Endocrinol Clin 1997;38:255–261.
- Salerno M, Militreni R, Bravaccio C, Micillo M, Capalbo D, Di Maio S, Tenore A: Effect of different doses of levothyroxine on growth and intellectual outcome at four years in congenital hypothyroidism. Thyroid 2002;12:45–52.
- Dubuis JM, Glorieux J, Richer F, Deal CL, Dussault JH, Van Vliet G: Outcome of severe congenital hypothyroidism: Closing the development gap with early high dose levothyroxine treatment. J Clin Endocrinol Metab 1996;81:222–227.
- Bongers-Schokking J, Koot HM, Wiersma D, Verkerk PH, de Muink Keiser-Schrama S: Influence of timing and dose thyroid hormone replacement on development in infants with congenital hypothyroidism. J Pediatr 2000;136:292–297.
- Working Group on Neonatal Screening of the European Society for Paediatric Endocrinology: Revised guidelines for neonatal screening programmes for primary congenital hypothyroidism. Horm Res 1999;52:49–52.
von Heppe JH, Krude H, l’Allemand D, Schnabel D, Grüters A: Improved practicability and individualized dosage of L-thyroxine by using a liquid solution in newborns and infants with congenital hypothyroidism (CH) (abstract P1-929). Pediatr Res 2001;49:156A.
- Rovet JF, Ehrlich RM, Sorbara DL: Effect of thyroid hormone levels on temperament in infants with congenital hypothyroidism by screening of neonates. J Pediatr 1989;114:63–68.
- Rovet JF, Ehrlich RM: Long-term effects of L-thyroxine therapy for congenital hypothyroidism. J Pediatr 1995;126:380–386.
Soon IL, Soon B, Daneman D, Rovet JF: The influence of etiology and treatment factors on intellectual outcome in congenital hypothyroidism. J Dev Pediatr 2001;22:376–384.
Py V, Boileau P, Rives S, Bain P, Toublanc J-E: Long-term outcome of IQ of children screened for congenital hypothyroidism (CH): Only follow-up parameters correlate positively (abstract P192). Horm Res 1998;48(suppl 3):71.
- Selva KA, Mandel SH, Rien L, Sesser D, Miyahira R, Skeels M, Nelson JC, LaFranchi SH: Initial treatment dose of L-thyroxine in congenital hypothyroidism. J Pediatr 2002;141:786–792.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.